Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples

Recent Patents on Biomarkers

Volumn 5, Issue 2, 2015, Pages 93-100

  Janyasupab, Metini ^a   Lee, Ying Hui ^b   Zhang, Yuan ^c   Liu, Chen W ^d   Cai, Jieyi ^e   Popa, Adriana ^f   Samia, Anna C ^f   Wang, Kuan W ^g   Xu, Jiaqiang ^c   Hu, Chi Chang ^h   Wendt, Michael K ^f   Schiemann, Barbara J ^f   Thompson, Cheryl L ⁱ   Yen, Yun ^j,k   Schiemann, William P ^f   Liu, Chung C ^l  

^a King's Monkut Institute of Technology   (Thailand)

^b Material Research Group   (Taiwan)

^c SHANGHAI UNIVERSITY   (China)

^d INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^e BROWN UNIVERSITY   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^h NATIONAL TSING HUA UNIVERSITY   (Taiwan)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^k TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^l Case Western Reserve University   (United States)

more..

Author keywords

Biomarker; Lysyl oxidase like 2 (LOXL2); Metastasis of breast cancers; Thin gold film biosensor

Indexed keywords

ALLYSINE; HYDROGEN PEROXIDE; LYSYL OXIDASE LIKE 2; PROTEIN LYSINE 6 OXIDASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CATALYSIS; CONTROLLED STUDY; DISEASE COURSE; ELECTROCHEMICAL DETECTION; ENZYMIC BIOSENSOR; FEMALE; HUMAN; METASTASIS; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 84977108202     PISSN: 22103090     EISSN: 22103104     Source Type: Journal    
DOI: 10.2174/2210309005666150804195033     Document Type: Article

References (37)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011; 61(6): 408-18.
2. Parvani JG, Taylor MA, Schiemann WP. Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2011; 16(2): 127-46.
3. Nguyen DX, Bos PD, Massague J. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84.
4. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-23.
5. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review 1975-2012. National Cancer Institute, Released on April 23, 2015.
6. Donegan W. Spratt JS. Cancer of the Breast(book) 5th Edition, London, UK, Elsevier Science Ltd., 2002.
7. Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: An update. Breast Cancer Res 2007; 9: 208-215.
8. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 2011; 378(9805): 1812-23.
9. Erler JT, Giaccia AJ. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 2006; 66(21): 10238-41.
10. Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer-a prospect. J Cell Biochem 2007; 101(6): 1338-54.
11. Nishioka T, Eustace A, West C. Lysyl oxidase: From basic science to future cancer treatment. Cell Struct Funct 2012; 37(1): 75-80.
12. Taylor MA, Amin J, Kirschmann DA, Schiemann WP. Lysyl oxidase contributes to mechanotransduction J -mediated regulation of transforming growth factor-signaling in breast cancer cells. Neoplasia 2011; 13(5): 406-18.
13. MeCauley, S., Smith, V. Catalytic domains from lysyl oxidase and LOXL2. US8927700 (2015).
14. McCauley, S., Hector, R., Carlos, A.G., Victoria, S. Antibodies that bind to lysyl oxidase-like 2 (LOXL2). US8680246 (2014).
15. Victoria, S., Scott, O., Peter, V.V., Vivian, E.B., Derek, M., Alison, K.H., Hector, R., Miho, O., Scott, A.M., Carlos, A.G., Donna, H.B. LOX and LOXL2 inhibitors and uses thereof. US8461303 (2013).
16. Scott, M., Victoria, S. Catalytic domains from lysyl oxidase and LOXL2. US8512990 (2013).
17. Torres S, Garcia-Palmero I, Herrera M, Barolome RA, Pena C, Fernandez-Acenero MJ, et al. LOXL2 is highly expressed in cancer-associated fibroblasta and associates to poor colon cancer survival. Clinical Cancer Research 2015; published Online First July 23,2015;dol:10.1158/1078-0432.CCR.14-3096.
18. Cano A, Santamaria PG, Moreno-Bueno G, LOXL2in epitheliar cell plasticity and tumor progression. Future Oncol 2012;8:1095-108.
19. Herranz N, Dave N, Millanes-Romero A, Morey L, Diaz VM, Lorenz-Fonfria V, et al. Lysyl oxidase-like 2 deaminates lysine4 in histone H3. Mol Cell 2012;46:369-76.
20. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 2011; 71(5): 1561-72.
21. Barker HE, Erler JE. The potential for LOXL2 as a target for future cancer treatment. Future Oncol 2011; 7(6): 707-10.
22. Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou, et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Sre/FAK pathway. Carcinogenesis 2009; 30: 1660-9.
23. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010; 29: 6485-98.
24. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010; 15: 169-90.
25. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Eng J Med 2005; 353: 1784-92.
26. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
27. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: Risk factors to potential targets. Clinical Cancer Research 2008; 14(24): 8010-8.
28. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clinical Breast Cancer 2009; 9: (Supplement 2): S73-81.
29. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 2012; 7: 683-92.
30. Duffy MJ. Serum tumor markers in breast cancer: Are they of clinical value? Clinical Chem 2006; 52(3): 345-51.
31. Brooks M. Breast cancer screening and biomarkers. Methods Mol Biol2009; 472: 307-21.
32. Moreno-Bueno G, Fernando S, Alberto M, Alfredo F, Eva PC, Vanesa S, et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med 2011; 3(9): 528-44.
33. Peinado H, Del Cidcm, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, et al. A molecular role for lysyl oxidase-like 2 enzyme in Snail regulation and tumor progression. EMBO J 2005; 24: 3446.
34. Peinado H, Portillo F, Cano A. Switching on-off snail: LOXL2 versus GSK3? Cell Cycle 2005; 4: 1749.
35. Peinado H, Moreno-Bueno G, Hardisson D, Pérez-Gómez E, Santos V, Mendiola M, et al. Lysyl Oxidase-Like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res 2008; 68: 4541.
36. Kagan HM, Li W. Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003; 88: 660.
37. Lucero HA, Kagan HM. Lysyl oxidase: An oxidative enzyme and effector of cell function. Cell Mol Life Sci 2006; 63: 2304.